Medical Management and Stroke Prevention
At a Glance
CARASAL care must balance ischemic stroke risk from blockages with brain-hemorrhage risk. Management focuses on individualized blood pressure control, careful decisions about blood-thinning medicines, cardiovascular risk reduction, and supportive care; no disease-modifying therapy is established.
Managing CARASAL is a delicate balancing act. Because the condition damages the small blood vessels in your brain, it places you at risk for two very different types of events: ischemic strokes (caused by a blockage) and intracerebral hemorrhages (caused by a bleed) [1].
Treatment strategies that prevent one type of stroke can sometimes increase the risk of the other. For this reason, your care must be highly individualized and managed by a vascular neurologist—a specialist in the brain’s blood vessels [2][3].
CRITICAL MEDICATION SAFETY WARNING:
- Never start, stop, or change the dose of an antiplatelet (like aspirin), an anticoagulant (like Eliquis or warfarin), or any blood pressure medication on your own.
- The guidance below is informational. Your doctor must make these decisions based on your specific MRI findings, prior history of hemorrhage, and overall cardiovascular health.
Controlling Blood Pressure
A central part of managing CARASAL is managing your blood pressure based on standard secondary stroke prevention guidelines. High blood pressure (hypertension) is a driver of small vessel damage and increases the risk of both blockages and bleeds [4][5].
Individualized Targets and Resistant Hypertension
In some families with CARASAL, hypertension is “therapy-resistant,” meaning it remains high even when taking several different blood pressure medications [4].
- Targets: While general stroke guidance often uses a starting target of 130/80 mm Hg, your specific goal must be set by your doctor [6][5]. Overly aggressive blood pressure lowering can cause orthostatic symptoms (dizziness when standing), falls, or inadequate blood flow to the brain in some people.
- Monitoring: Home blood pressure monitoring is often recommended so your team can safely adjust medications.
The Blood Thinner Dilemma
In many common types of stroke, doctors routinely prescribe antiplatelets (like aspirin or clopidogrel) or anticoagulants to prevent future blockages [3]. In CARASAL, this decision is much more complex.
Because CARASAL involves a known risk of brain bleeds, “blood thinners” must be approached carefully [1].
- Individualized Choice: There is no universal ban on antiplatelets or anticoagulants for CARASAL. You may have a strong, separate medical indication for them (such as atrial fibrillation, a mechanical heart valve, or a recent coronary stent). Your doctor will weigh these needs against the presence of microbleeds (tiny old bleeds) seen on your MRI [2][3].
- Combination Therapies: The long-term routine use of two blood thinners at the same time is generally scrutinized closely due to hemorrhage risks, though it may be required temporarily for acute stroke protocols or cardiac reasons [1][3].
Investigational Treatments
Currently, there are no established “disease-modifying” therapies that can stop the progression of CARASAL. Research is looking at the role of endothelin-1, the protein hypothesized to build up because of the CTSA gene mutation [7].
- Endothelin Antagonists: Drugs that block endothelin-A receptors (such as zibotentan) are being studied in other conditions, but they have not been proven safe or effective for patients with CARASAL in human clinical trials [8][9]. Using these medications “off-label” is not standard care, partly because laboratory evidence suggests endothelin-1 might also play necessary roles in brain repair [10].
- Gene Therapy: Concepts to replace the missing cathepsin A function remain in early laboratory and animal stages [11].
Comprehensive Cardiovascular Prevention
Beyond medications, managing your overall vascular health helps protect your blood vessels based on standard cardiovascular risk management:
- Cholesterol Management: Using statins may be recommended based on your individual cardiovascular risk profile to prevent larger vessel blockages [12][13].
- Lifestyle Factors: Quitting smoking, managing blood sugar, and following a heart-healthy diet reduce overall stress on your vessels [14][15].
- Supportive Care: Integrated care that includes psychological support and rehabilitation (physical or occupational therapy) is a vital part of long-term management [16][2].
Common questions in this guide
How are blood-thinning medicines chosen for someone with CARASAL?
What blood pressure goal is used for CARASAL?
Is there a treatment that can stop CARASAL from progressing?
What lifestyle changes can reduce vascular risk with CARASAL?
What happens if high blood pressure remains high despite several medicines?
How can MRI findings affect CARASAL treatment decisions?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Cathepsin A-related arteriopathy-strokes-leukoencephalopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How are we balancing my risk for ischemic blockages against the risk of brain hemorrhage when deciding on antiplatelet or anticoagulant use?
- 2.If my blood pressure remains high despite several medications, what are our next steps for management?
- 3.Based on my individual cardiovascular profile, what are my personalized blood pressure and cholesterol targets?
- 4.How often should my MRI be repeated to monitor for new microbleeds, and will those results change my treatment plan?
- 5.Are there any clinical trials or research centers you recommend that focus specifically on new treatments for CARASAL?
References
References (16)
- 1
Expanding the Clinicoradiologic Phenotype of the CTSA-Associated Small Vessel Disease CARASAL: A Comparison With CADASIL.
Cerfontaine MN, Gravesteijn G, Hack RJ, et al.
Neurology. Genetics 2026; (12(2)):e200358 doi:10.1212/NXG.0000000000200358.
PMID: 41908989 - 2
Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology.
Mancuso M, Arnold M, Bersano A, et al.
European journal of neurology 2020; (27(6)):909-927 doi:10.1111/ene.14183.
PMID: 32196841 - 3
Updates on Prevention of Hemorrhagic and Lacunar Strokes.
Tsai HH, Kim JS, Jouvent E, Gurol ME
Journal of stroke 2018; (20(2)):167-179 doi:10.5853/jos.2018.00787.
PMID: 29886717 - 4
Cathepsin A-related arteriopathy with strokes and leukoencephalopathy (CARASAL).
Bugiani M, Kevelam SH, Bakels HS, et al.
Neurology 2016; (87(17)):1777-1786 doi:10.1212/WNL.0000000000003251.
PMID: 27664989 - 5
ESO Guideline on covert cerebral small vessel disease.
Wardlaw JM, Debette S, Jokinen H, et al.
European stroke journal 2021; (6(2)):CXI-CLXII doi:10.1177/23969873211012132.
PMID: 34414301 - 6
2021 Taiwan Stroke Society Guidelines of blood pressure control for ischemic stroke prevention.
Chi NF, Chung CP, Cheng HM, et al.
Journal of the Chinese Medical Association : JCMA 2022; (85(6)):651-664 doi:10.1097/JCMA.0000000000000738.
PMID: 35507097 - 7
Update on hereditary, autosomal dominant cathepsin-A-related arteriopathy with strokes and leukoencephalopathy (CARASAL).
Finsterer J, Scorza CA, Scorza FA, Wakil SM
Acta neurologica Belgica 2019; (119(3)):299-303 doi:10.1007/s13760-019-01158-8.
PMID: 31177426 - 8
Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial.
Morrow AJ, Ford TJ, Mangion K, et al.
American heart journal 2020; (229()):70-80 doi:10.1016/j.ahj.2020.07.007.
PMID: 32942043 - 9
Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction.
Ford TJ, Corcoran D, Padmanabhan S, et al.
European heart journal 2020; (41(34)):3239-3252 doi:10.1093/eurheartj/ehz915.
PMID: 31972008 - 10
Endothelin-1 signaling maintains glial progenitor proliferation in the postnatal subventricular zone.
Adams KL, Riparini G, Banerjee P, et al.
Nature communications 2020; (11(1)):2138 doi:10.1038/s41467-020-16028-8.
PMID: 32358570 - 11
Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent.
Itoh K, Tsukimoto J
Glycoconjugate journal 2023; (40(6)):611-619 doi:10.1007/s10719-023-10135-6.
PMID: 38147151 - 12
Lipid management for primary and secondary stroke prevention consensus paper of the International Lipid Expert Panel (ILEP).
Banach M, Toth PP, Ahn HJ, et al.
Progress in cardiovascular diseases 2026; (94()):78-110 doi:10.1016/j.pcad.2025.11.003.
PMID: 41249078 - 13
Interpretation of the evidence for the efficacy and safety of statin therapy.
Collins R, Reith C, Emberson J, et al.
Lancet (London, England) 2016; (388(10059)):2532-2561 doi:10.1016/S0140-6736(16)31357-5.
PMID: 27616593 - 14
Secondary stroke prevention beyond antiplatelets: The role of colchicine and GLP-1RA - an ounce of prevention is worth a pound of cure.
Mijajlović MD, Bornstein NM, Aleksić V
Therapeutic advances in neurological disorders 2025; (18()):17562864251326769 doi:10.1177/17562864251326769.
PMID: 40291758 - 15
Life Style and Behavioural Factors are Associated with Stroke Recurrence Among Survivors of First Episode of Stroke: A Case Control Study.
Shani SD, Varma RP, Sarma PS, et al.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2021; (30(4)):105606 doi:10.1016/j.jstrokecerebrovasdis.2021.105606.
PMID: 33548808 - 16
From Three-Months to Five-Years: Sustaining Long-Term Benefits of Endovascular Therapy for Ischemic Stroke.
Ganesh A, Ospel JM, Marko M, et al.
Frontiers in neurology 2021; (12()):713738 doi:10.3389/fneur.2021.713738.
PMID: 34381418
This page is for informational purposes only and does not constitute medical advice. Because CARASAL can involve both ischemic stroke and brain-bleed risk, consult your vascular neurologist before changing any medicine.